Stock Analysis

China Health Group First Half 2024 Earnings: EPS: CN¥0.007 (vs CN¥0.006 in 1H 2023)

SEHK:8225
Source: Shutterstock

China Health Group (HKG:8225) First Half 2024 Results

Key Financial Results

  • Revenue: CN¥18.3m (up 22% from 1H 2023).
  • Net income: CN¥7.35m (up 26% from 1H 2023).
  • Profit margin: 40% (up from 39% in 1H 2023). The increase in margin was driven by higher revenue.
  • EPS: CN¥0.007 (up from CN¥0.006 in 1H 2023).
earnings-and-revenue-history
SEHK:8225 Earnings and Revenue History October 1st 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

China Health Group shares are down 8.3% from a week ago.

Risk Analysis

Be aware that China Health Group is showing 4 warning signs in our investment analysis and 1 of those shouldn't be ignored...

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.